Arthneeti
NF

NGL Fine Chem Ltd

Q1 FY27Pharmaceuticals & Biotechnology

NGL Fine Chem Ltd Q1 FY27 Results & Presentation Highlights: Revenue ₹139.16 Cr, PAT ₹18.40 Cr

Q1 FY27 investor presentation: what the company reported on revenue, margins and projects.

Price₹2,895
Market cap₹1.7K Cr
P/E33.9
Updated24 Sept 2026
Read4 min read

Based on NGL Fine Chem Ltd's Q1 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.

The short version

Quarterly Revenue (Q1FY27): ₹139.16 crores - Year-on-Year (YoY) growth: 33.57% - Revenue from Operations: ₹139.16 crores in Q1FY27 (vs. EBITDA for Q1FY27: ₹23.29 crores, up 112.21% YoY - EBITDA Margin for Q1FY27: 16.73%, up 620 basis points YoY - Profit After Tax (PAT) for Q1FY27: ₹18.40 crores, up 99.09% YoY - Operating expense

From NGL Fine Chem Ltd's Q1 FY27 earnings-call transcript · updated 24 Sept 2026.

Revenue & Sales Performance

  • Quarterly Revenue (Q1FY27): ₹139.16 crores
  • Year-on-Year (YoY) growth: 33.57%
  • Revenue from Operations: ₹139.16 crores in Q1FY27 (vs. ₹104.19 crores in Q1FY26)
  • Other Income: ₹7.43 crores in Q1FY27, up 16.91% YoY
  • Total Income: ₹146.59 crores in Q1FY27, up 32.61% YoY
  • Volume Outlook: Management commentary states sustained demand momentum with volumes remaining robust across product segments and geographies.

2 more points management made on revenue & sales performance

Profitability & Margins

See what NGL Fine Chem Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Greenfield expansion at Tarapur:
  • A larger expansion to drive the next leg of exponential growth.
  • Estimated capex of ₹210 crore.
  • Funded through debt and internal accrual.
  • Civil construction underway, with ₹209.71 crore invested till Q1FY27.
  • Commercial production expected to start from H2FY27.
  • Phase II Capex:
  • On schedule for commissioning during the current quarter (Q1FY27).
  • Total project cost and scope remain unchanged.
  • Expected to commence commercial production from H2FY27.
  • Incremental capacity to support growth plans and new market opportunities.
  • Completed expansion in subsidiary Macrotech:

2 more points management made on capital expenditure plans

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

5x potential
1KRM Ayurveda Ltd
Rev 1Mar 1
2Accretion Pharmaceuticals Ltd
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what NGL Fine Chem Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The investor presentation does not explicitly report any figures or details regarding: - Order book - Order inflow - Pending orders No sections or data in the provided pages mention the values or status of order backlog or inflow. The presentation focuses on financial performance, segmental revenue, manufacturing capacity, key initiatives, margins, and management commentary but does not disclose order book or order inflow details.

NGL Fine Chem Ltd — Quarterly revenue & net profit

Revenue Net profit Net loss
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹145 Cr, net profit ₹11 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What NGL Fine Chem Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • Morepen Laboratories Ltd (Q1 FY27)

    575.31 Cr (Page 4) . Key investor presentation takeaways from Morepen Laboratories Ltd's Q1 FY27 investor presentation — and how it ranks against sector peers.

  • Procter & Gamble Health Ltd (Q1 FY27)

    FY 2025-26 sales grew by +16% year-on-year, indicating strong consistent balanced growth (Page 8). Key investor presentation takeaways from Procter & Gamble Hea

  • Jubilant Pharmova Ltd (Q1 FY27)

    2,229 Cr., up 17% YoY (Page 97) . Key investor presentation takeaways from Jubilant Pharmova Ltd's Q1 FY27 investor presentation — and how it ranks against sect

  • Beta Drugs Ltd (Q1 FY27)

    Q1-FY27 revenue from operations: INR 1,255 Mn, up 25.2% YoY from INR 1,002 Mn in Q1-FY26 (Page 32). Key investor presentation takeaways from Beta Drugs Ltd's Q1

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were NGL Fine Chem Ltd Q1 FY27 results?

Quarterly Revenue (Q1FY27): ₹139.16 crores - Year-on-Year (YoY) growth: 33.57% - Revenue from Operations: ₹139.16 crores in Q1FY27 (vs. EBITDA for Q1FY27: ₹23.29 crores, up 112.21% YoY - EBITDA Margin for Q1FY27: 16.73%, up 620 basis points YoY - Profit After Tax (PAT) for Q1FY27: ₹18.40 crores, up 99.09% YoY - Operating expense

What is NGL Fine Chem Ltd share price analysis?

NGL Fine Chem Ltd currently shows a neutral. The stock trades at a P/E of 33.9 with a market cap of ₹1,711 Cr. Investors should review the full earnings analysis for detailed insights.

Is NGL Fine Chem Ltd planning capital expenditure?

Greenfield expansion at Tarapur: - A larger expansion to drive the next leg of exponential growth.

Keep NGL Fine Chem Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.